Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer
Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer
Active, not recruiting · NCT04223856 · Registry updated 2026-05-29Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer | Urothelial Cancer | Active, not recruiting | Phase 3 | 2026-05-29 | NCT04223856 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Astellas Pharma Global Development, Inc. | 43 |
| Merck Sharp & Dohme LLC | 650 |
| Seagen Inc. | 31 |
260 results · Page 1 of 11
Research sites
Swipe the table sideways for more columns.